| Drug Name |
Orlistat |
| Drug ID |
BADD_D01624 |
| Description |
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.[A229928]
Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.[L11130] This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter[L31963] and prescription preparations, depending on the dosage quantity.[L11130] |
| Indications and Usage |
For obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Also used to reduce the risk for weight regain after prior weight loss. Use of orlistat is pending revision due to reports of liver-related adverse events. |
| Marketing Status |
Prescription; OTC |
| ATC Code |
A08AB01 |
| DrugBank ID |
DB01083
|
| KEGG ID |
D04028
|
| MeSH ID |
D000077403
|
| PubChem ID |
3034010
|
| TTD Drug ID |
D0T9TJ
|
| NDC Product Code |
62331-045; 71973-001; 51927-5020; 0135-0461; 71052-110; 66499-0043; 61269-460 |
| Synonyms |
Orlistat | Tetrahydrolipstatin | THLP | Tetrahydrolipastatin | Ro-18-0647 | Ro 18 0647 | Alli | 1-((3-Hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate | Xenical |
